XNASREPL
Market cap868mUSD
Jan 08, Last price
11.53USD
1D
2.95%
1Q
3.69%
IPO
-23.13%
Name
Replimune Group Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
23.47%
Rev. gr., 5y
%
Revenues
0k
Net income
-216m
L+23.82%
CFO
-185m
L+44.84%
Earnings
Feb 06, 2025
Profile
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | 177,618 | 128,974 | 84,120 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (177,618) | (128,974) | (84,120) | |||||
NOPBT Margin | ||||||||
Operating Taxes | 408 | 288 | 1,164 | |||||
Tax Rate | ||||||||
NOPAT | (178,026) | (129,262) | (85,284) | |||||
Net income | (215,794) 23.82% | (174,284) 47.65% | (118,036) 45.96% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 1,759 | 187,292 | 6,862 | |||||
BB yield | -0.32% | -18.22% | -0.77% | |||||
| Debt | ||||||||
Debt current | 7,758 | 3,757 | 3,632 | |||||
Long-term debt | 103,050 | 89,113 | 62,046 | |||||
Deferred revenue | ||||||||
Other long-term liabilities | 786 | 472 | ||||||
Net debt | (309,860) | (492,152) | (331,613) | |||||
| Cash flow | ||||||||
Cash from operating activities | (185,467) | (128,050) | (82,180) | |||||
CAPEX | (5,662) | (2,270) | (2,336) | |||||
Cash from investing activities | 97,201 | (142,502) | (1,806) | |||||
Cash from financing activities | 16,283 | 311,303 | 6,598 | |||||
FCF | (178,029) | (126,035) | (83,148) | |||||
| Balance | ||||||||
Cash | 420,668 | 583,386 | 395,655 | |||||
Long term investments | 1,636 | 1,636 | ||||||
Excess cash | 420,668 | 585,022 | 397,291 | |||||
Stockholders' equity | (696,366) | (479,702) | (312,130) | |||||
Invested Capital | 1,151,408 | 1,074,515 | 756,198 | |||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 66,570 | 58,213 | 52,212 | |||||
Price | 8.17 -53.74% | 17.66 4.00% | 16.98 -44.35% | |||||
Market cap | 543,876 -47.10% | 1,028,042 15.96% | 886,564 -37.17% | |||||
EV | 234,016 | 535,890 | 554,951 | |||||
EBITDA | (174,963) | (126,527) | (81,973) | |||||
EV/EBITDA | ||||||||
Interest | 4,160 | 2,223 | ||||||
Interest/NOPBT | ||||||||